Aquatic Capital Management LLC Purchases Shares of 4,867 GeneDx Holdings Corp. (NASDAQ:WGS)

Aquatic Capital Management LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 4,867 shares of the company's stock, valued at approximately $374,000.

Several other hedge funds have also added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of GeneDx by 346.3% in the 3rd quarter. Barclays PLC now owns 18,921 shares of the company's stock valued at $803,000 after purchasing an additional 14,681 shares during the period. Prudential Financial Inc. acquired a new position in GeneDx in the fourth quarter valued at about $7,938,000. JPMorgan Chase & Co. lifted its stake in GeneDx by 617.3% in the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company's stock valued at $2,214,000 after buying an additional 44,889 shares during the period. Principal Financial Group Inc. bought a new position in GeneDx during the third quarter worth about $604,000. Finally, Raymond James Financial Inc. acquired a new position in shares of GeneDx during the 4th quarter worth about $20,371,000. Institutional investors own 61.72% of the company's stock.

Analyst Upgrades and Downgrades

WGS has been the topic of several recent analyst reports. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Wells Fargo & Company reduced their price target on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. TD Cowen upped their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. Finally, TD Securities dropped their price objective on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $78.14.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 402 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the transaction, the chief financial officer now owns 5,044 shares in the company, valued at $454,212.20. This trade represents a 7.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Katherine Stueland sold 2,154 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total value of $243,595.86. Following the sale, the chief executive officer now owns 3,440 shares in the company, valued at $389,029.60. The trade was a 38.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 139,390 shares of company stock worth $13,043,288. Corporate insiders own 27.30% of the company's stock.

GeneDx Stock Down 4.4 %

Shares of WGS stock traded down $2.89 during trading hours on Tuesday, hitting $63.27. 1,694,225 shares of the company were exchanged, compared to its average volume of 724,830. GeneDx Holdings Corp. has a 52 week low of $18.80 and a 52 week high of $117.75. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average of $93.64 and a two-hundred day moving average of $82.95. The company has a market capitalization of $1.78 billion, a PE ratio of -32.28 and a beta of 1.96.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.17. The firm had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.